In the past week, ABVC stock has gone up by 32.61%, with a monthly gain of 78.10% and a quarterly surge of 205.38%. The volatility ratio for the week is 7.17%, and the volatility levels for the last 30 days are 9.52% for ABVC BioPharma Inc The simple moving average for the past 20 days is 34.62% for ABVC’s stock, with a 197.03% simple moving average for the past 200 days.
Is It Worth Investing in ABVC BioPharma Inc (NASDAQ: ABVC) Right Now?
Company’s 36-month beta value is 0.31.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ABVC is 14.55M, and currently, short sellers hold a 3.49% ratio of that floaft. The average trading volume of ABVC on June 27, 2025 was 415.76K shares.
ABVC) stock’s latest price update
ABVC BioPharma Inc (NASDAQ: ABVC)’s stock price has soared by 11.42 in relation to previous closing price of 2.19. Nevertheless, the company has seen a gain of 32.61% in its stock price over the last five trading days. globenewswire.com reported 2024-12-11 that FREMONT, Calif., Dec. 11, 2024 (GLOBE NEWSWIRE) — ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company advancing therapeutic solutions in ophthalmology, CNS (central nervous system), and oncology/hematology, announced the receipt of a $200,000 cash payment from OncoX BioPharma Inc. (“OncoX”) as part of its strategic licensing agreement for certain oncology-related products; this payment marks the first installment of $5 million in potential licensing fees from OncoX. With this payment, the total accumulated cash payment ABVC has received from its three strategic partners for licensing various ABVC products is $546,000. ABVC and its subsidiaries BioLite Inc. and Rgene Corporation are each eligible to receive up to 10M OncoX shares, $5M cash payment, and royalties up to $50M after the product launches.1
ABVC Trading at 70.81% from the 50-Day Moving Average
After a stumble in the market that brought ABVC to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 6.55% of gains for the given period.
Stock Fundamentals for ABVC
Current profitability levels for the company are sitting at:
- -3.84 for the present operating margin
- 1.0 for the gross margin
The net margin for ABVC BioPharma Inc stands at -3.56. The total capital return value is set at -0.24. Equity return is now at value -27.00, with -12.26 for asset returns.
Based on ABVC BioPharma Inc (ABVC), the company’s capital structure generated 0.29 points at debt to capital in total, while cash flow to debt ratio is standing at -0.75. The debt to equity ratio resting at 0.4. The interest coverage ratio of the stock is -5.37.
Currently, EBITDA for the company is -4.34 million with net debt to EBITDA at -1.21. When we switch over and look at the enterprise to sales, we see a ratio of 85.97. The receivables turnover for the company is 0.95for trailing twelve months and the total asset turnover is 0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.22.
Conclusion
In a nutshell, ABVC BioPharma Inc (ABVC) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
